
Teil der Reihe: Medicine (R0)
Long-Acting Injectable Medications in Mental Health
Inhaltsangabe
Introduction.- History of LAIs.- Brief guidance on use of LAIs- where are the current guidelines.- Evidence of Effectiveness.- First Generation Antipsychotic LAIs.- Haloperidol.- Fluphenazine.- Aripiprazole Products.- Abilify Maintena.- Abilify Asimtufii.- Aristada (to include Initio).- Paliperidone.- Invega Sustenna.- Invega Trinza.- Invega Hafyera.- Risperidone.- Risperdal Consta (to include information on generic availability).- Perseris.- Uzedy.- Rykindo.- Olanzapine.- Zyprexa Relprevv.- Naltrexone.- Vivitrol.- Buprenorphine.- Sublocade.- Brixadi.- Special Populations.- Pediatrics.- Older Adults.- Pregnancy and Lactation.- Approaching the Patient and Successful Utilization.- Successful discussions.- Clinic set-up.- Pharmacist Administration.- Future of LAIs.- Discussion of future products and where practice is headed.- Conclusion.- Medication Reference Tables.
Produktdetails
- Erscheinungsdatum: 20.11.2025
- Autor/Autorin: Megan J. Ehret
- Reihe: Medicine (R0)
- Format: E-Book
- Dateiformat: PDF
- Kopierschutz: Wasserzeichen
- Dateigröße: 6 MB
- Verlag: SPRINGER
- Sprache: Englisch
- Umfang: 128 Seiten
- ISBN: 9783032094155
- Lieferung: Sofort per Download
- Hinweis: Sofort per Download lieferbar. Kein physischer Versand.
- Kompatibilität: Lesbar auf Geräten und Apps mit PDF-Unterstützung.
Includes LAI formulation, dosing parameters, pharmacokinetic properties, drug interactions, administration instructions Provides guidance on switching strategies between agents and discontinuation options for patients Discuses use of LAIs in special populations (pediatric, geriatric, pregnant and lactating patients)
Herstellerinformationen
Email: ProductSafety@springernature.com











